Focus:
Deals Analysis
-
20 May 2020
Canadian Government invests $175.6m in AbCellera’s Covid-19 response
AbCellera has received $175.6m through the Canadian Government’s Strategic Innovation Fund to support the development and manufacturing of antibody drugs against Covid-19, as well as allow for better preparedness for...
-
12 May 2020
AbbVie acquires Allergan: unpicking the year-long approval process
AbbVie’s $63bn acquisition of Allergan has been in the works since June 2019. It aims to diversify AbbVie’s portfolio beyond its blockbuster product Humira and create cost efficiencies in R&D...
-
7 May 2020
Beyond M&As: will 2020 by the year of the spin-out?
Last year saw extensive M&A activity in pharma, centred around large scale multi-billion-dollar megamergers. With the year of the megamerger now behind us, what will be the new commercial trend...
-
7 May 2020
Vertex-Affinia partnership: expanding the gene therapy toolkit
Building on the success of its gene-targeted cystic fibrosis therapies, Vertex has begun to expand into new disease areas that would benefit from a similar gene therapy approach. To this...
-
4 May 2020
Three big pharma VC arms bet on FoRx’s novel cancer approach
The VC wings of three big pharma companies – Novartis, Pfizer and the Merck group – have all continued their support for Swiss oncology biotech FoRx in its seed round....
-
28 April 2020
Takeda-Orifarm deal: another divestiture for the Japanese pharma giant
In keeping with its long-term business strategy, Japanese pharma giant Takeda has divested 110 over-the-counter and prescription pharma products to Orifarm. The $670m deal is the latter’s largest acquisition to...
-
21 April 2020
Asia-Pacific witnesses 5.4% increase in deal activity during week ended 19 April 2020
Data and analytics company GlobalData has revealed that deal activity in the Asia-Pacific region has shown signs of revival during the week ended 19 April 2020.
-
21 April 2020
Breakthrough in neurodegeneration: GV, Bill Gates and Foresight invest $45m in Cerevance
GV, Bill Gates and Foresight Capital joined three existing investors in Cerevance’s recent Series B round, which closed with $45m raised. The ability of this brain disease-focused drug discovery company...
-
16 April 2020
Global deal activity decreases 17.2% with 899 deals last week
A total of 899 deals were announced globally during the week ended 12 April 2020, registering a 17.2% drop when compared to 1,086 deals announced during the previous week, according...
-
15 April 2020
Blackstone’s $2bn investment in Alnylam: betting on RNAi therapeutics
On Monday 13 April, Blackstone announced it had invested up to $2bn in Alnylam Pharmaceuticals, which is a pioneer in the field of RNA interference (RNAi) medicines across a wide...